SG Americas Securities LLC Has $523,000 Stake in Compass Therapeutics, Inc. $CMPX

SG Americas Securities LLC reduced its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 59.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 149,313 shares of the company’s stock after selling 223,368 shares during the quarter. SG Americas Securities LLC owned 0.11% of Compass Therapeutics worth $523,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Vivo Capital LLC grew its position in shares of Compass Therapeutics by 70.0% in the 2nd quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after purchasing an additional 2,487,443 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Compass Therapeutics by 11.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after buying an additional 449,868 shares during the period. Simplicity Wealth LLC increased its position in shares of Compass Therapeutics by 81.8% during the second quarter. Simplicity Wealth LLC now owns 84,636 shares of the company’s stock worth $220,000 after acquiring an additional 38,093 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Compass Therapeutics during the second quarter worth $84,000. Finally, Marex Group plc acquired a new stake in shares of Compass Therapeutics during the second quarter worth $61,000. Institutional investors own 68.43% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on CMPX shares. Leerink Partners upgraded Compass Therapeutics to a “strong-buy” rating in a report on Wednesday, November 26th. Citizens Jmp assumed coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price objective for the company. Canaccord Genuity Group initiated coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $10.00 target price on the stock. Wall Street Zen downgraded Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 17th. Finally, Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “overweight” rating for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $5.90 on Friday. The stock has a 50 day moving average price of $5.31 and a 200 day moving average price of $4.14. The stock has a market capitalization of $1.05 billion, a PE ratio of -13.11 and a beta of 1.45. Compass Therapeutics, Inc. has a 52 week low of $1.33 and a 52 week high of $6.40.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. As a group, research analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.